Psoriasis Comorbidities at Hospital Calderón Guardia
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age12+
SponsorCaja Costarricense de Seguro Social
About this trial
The goal of this observational study is to characterize the epidemiologic, clinical, severity, and therapeutic features of patients with psoriasis treated in Costa Rica between 2024 and 2025. The main questions it aims to answer are:
What are the demographic and clinical characteristics and severity profiles of psoriasis patients?
What treatments are used in routine clinical practice, and how are they associated with disease severity and outcomes?
Patients with psoriasis receiving dermatologic care during the study period will be included. Data will be obtained retrospectively from electronic medical records and clinical registries without intervention or modification of treatment.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Patients evaluated in outpatient clinics during the period 2024-2025.
Patients receiving systemic therapy and/or phototherapy.
Patients aged 12 years or older, of any sex.
Availability of sufficient clinical information to assess psoriasis severity, metabolic comorbidities, atherosclerotic cardiovascular disease, and psoriatic arthritis.
Disqualifiers
Clinical records insufficient to evaluate psoriasis severity, comorbidities, or therapeutic profile.
Patients managed exclusively with topical therapies.
Duplicate or inconsistent records, preventing accurate patient classification.
Cutaneous conditions not compatible with psoriasis.
Trial population
The study population comprises adolescents and adults (≥12 years) with a confirmed diagnosis of psoriasis documented in the Electronic Health Record (EHR-EDUS) of Hospital Calderón Guardia who were evaluated in outpatient dermatology or rheumatology clinics between 2024 and 2025. Eligible patients received systemic therapy and/or phototherapy for psoriasis and had sufficient clinical information to assess disease severity, metabolic comorbidities, atherosclerotic cardiovascular disease, and psoriatic arthritis. This hospital-based cohort reflects real-world patients with moderate-to-severe psoriasis managed in specialized care within the Costa Rican public health system during the study period.
Trial design
Design model
Cohort
Time perspective
Retrospective
Treatments tested in this trial
Not listed
Trial groups
No trial groups listed
Trial outcomes
Primary outcomes
1
Prevalence of Metabolic Comorbidities in Patients With Psoriasis
Proportion (%) of patients with documented diagnosis of obesity (BMI ≥30 kg/m²), diabetes mellitus (prior diagnosis or HbA1c ≥6.5%), hypertension (prior diagnosis or BP ≥140/90 mmHg), dyslipidemia (prior diagnosis or abnormal lipid profile), and metabolic syndrome.
Time frame
2024-20252
Prevalence of Atherosclerotic Cardiovascular Disease
Proportion (%) of patients with documented history of coronary artery disease, myocardial infarction, angina/revascularization, ischemic stroke, or peripheral arterial disease.
Time frame
2024-20253
Prevalence of Psoriatic Arthritis
Proportion (%) of patients with rheumatologist-confirmed diagnosis of psoriatic arthritis, including characterization of predominant clinical domain (peripheral arthritis, axial involvement, enthesitis, dactylitis).
Time frame
2024-2025Secondary outcomes
1
Psoriasis Severity
Psoriasis Area and Severity Index (PASI), continuous score (0-72), categorized as mild (\<10), moderate (10-20), or severe (\>20).
Time frame
2024-20252
Psoriasis Severity
Body Surface Area (BSA) Affected, percentage of body surface area affected by psoriasis
Time frame
2024-20253
Association Between Psoriasis Severity and Comorbidities
Statistical association between severity categories and presence of metabolic comorbidities, atherosclerotic disease, and psoriatic arthritis using chi-square, Fisher's exact test, t-test or Mann-Whitney U test.
Time frame
2024-20254
Inflammatory and Metabolic Biomarkers
Continuous values of C-reactive protein, erythrocyte sedimentation rate, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, monocyte-to-lymphocyte ratio, cardiac troponin, B-type natriuretic peptide, total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, triglycerides, fasting plasma glucose, glycated hemoglobin, serum creatinine, estimated glomerular filtration rate, aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase, and total bilirubin.
Time frame
2024-2025Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov
This trial is not recruiting at the moment. You can still explore other options: